From the sea to anticancer therapy

Current Medicinal Chemistry

Volumn 18, Issue 23, 2011, Pages 3551-3562

  Russo, P ^a   Nastrucci, C ^a   Cesario, A ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti cancer therapy; Clinical trial; EMEA approval; FDA approval; Marine compound; Mechanism of action; Pre clinical trial; Synthetic compound

Indexed keywords

AE 941; BRYOSTATIN 1; CYTARABINE; DEHYDRODIDEMNIN B; DISCODERMOLIDE; ERIBULIN; ES 285; GEMCITABINE; LYPRINOL; NSC339555; OMEGA CONOTOXIN MVIIA; SALINOSPORAMIDE A; SPHINGOSINE DERIVATIVE; SPISULOSINE; TASIDOTIN; TRABECTEDIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; NEUROMUSCULAR TOXICITY; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; AQUATIC ORGANISMS; BIOLOGICAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS;

EID: 80052060272     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796642652     Document Type: Article

References (152)

1. http://jv.gilead.org.il/martin/20000-1-02.html (Accessed February 12, 2011).
2. http://www.archaeologiemuseum.it/it/oetzi-uomo-venuto-dal-ghiaccio (Accessed February 12, 2011).
3. Lockermann, G.; Serturner, F. W. The discoverer of morphine. J. Chem. Educ., 1951, 28, 277.
4. Newman, D.J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem., 2008, 51, 2589-2599. (Pubitemid 351620778)
5. Cragg, G.M.; Newman, D.J. Plants as a source of anticancer agents; in Ethnopharmacology; Elisabetsky, Etkin, Eds. in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK, [http://www.eolss.net] (Accessed February 12, 2011).
6. Faulkner, D.J. Marine pharmacology. Antonie Van Leeuwenhoek, 2000, 77, 135-145. (Pubitemid 30160413)
7. Scheuer, P.J. Some marine ecological phenomena - chemical basis and biomedical potential. Science, 1990, 248, 173-177.
8. Kinghorn, A.D.; Chin, Y.W.; Swanson, S.M. Discovery of natural product anticancer agents from biodiverse organisms. Curr. Opin. Drug Discov. Devel., 2009, 12, 189-196.
9. Robak, T.; Wierzbowska, A. Current and emerging therapies for acute myeloid leukemia. Clin. Ther., 2009, 31, 2349-2370.
10. Goffin, J.; Lacchetti, C.; Ellis, P.M.; Ung, Y.C.; Evans, W.K. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J. Thorac. Oncol., 2010, 5, 260-274.
11. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477. (Pubitemid 46595760)
12. www.fiercebiotech.com/fda-approval (Accessed February 12, 2011).
13. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion- Initial-authorisation/human/002084/WC500101044.pdf. (Accessed February 12, 2011).
14. http://www.prnewswire.co.uk (Accessed February 12, 2011).
15. Bergmann, W.; Feeney, R.J. Contributions to the Study of Marine Products. XXXII. The Nucleosides of Sponges. I. J. Org. Chem., 1951, 16, 981-987.
16. Bergmann, W.; Feeney, R J. The Isolation of a New Thymine Pentoside from Sponges. J. Am. Chem. Soc., 1950, 72, 2809.
17. Watson, J.D.; Crick, F. Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid. Nature, 171, 1953, 4356, 737-738.
18. http://pushpanjalihealthcare.co (Accessed February 12, 2011).
19. Secrist, J.A. 3rd. Nucleosides as anticancer agents: from concept to the clinic. Nucleic Acids Symp. Ser., Oxford UK, 2005, 49, 15-16.
20. Cohen, S.S.; Flaks, J.G.; Barner, H.D.; Loeb, M.R.; Lichtenstein, J. The mode of action of 5-fluorouracil and its derivatives. Proc. Nat. Acad. Science (USA), 1958, 44, 1004-1012.
21. Freireich, E.J.; Gehan, E.A.; Rail, D.P.; Schmidt, L.H.; Skipper, H.E. Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man. Cancer Chemother. Rep., 1966, 50, 219-244.
22. Skipper, H.E. Criteria associated with destruction of leukemia and solid tumor cells in animals. Cancer Res., 1967, 27, 2636-2645.
23. Skipper, H.E.; Perry, S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res., 1970; 30, 1883-1897.
24. Seif, A.E.; Reilly, A.F.; Rheingold, S.R. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature. J. Pediatr. Hematol. Oncol., 2010, 32:, e349-352.
25. Hertel, L.W.; Kroin, J.S.; Grossman, C.S.; Grindey, G.B.; Dorr, A.F.; Storniolo, A.M.V.; Plunkett, W.; Gandhi, V.; Huang, P. Synthesis and Biological Activity of 2',2'-Difluorodeoxycytidine (Gemcitabine) in Biomedical Frontiers of Fluorine Chemistry Chapter 19, pp 265-278 ACS Symposium Series, Vol. 639 August 13, 1996.
26. Merl, M.Y.; Abdelghany, O.; Li, J.; Saif, M.W. First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. J. Pancreas (Online), 2010, 11, 317-320.
27. Javle, M., Hsueh, C.T. Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American society of clinical oncology. J. Hematol. Oncol., 2010, 3, 11.
28. Ramalingam, S.; Belani, C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist, 2008, 13 Suppl., 1, 5-13.
29. Mauri, D.; Polyzos, N.P.; Salanti, G.; Pavlidis, N.; Ioannidis, J.P. Multipletreatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J. Natl. Cancer Inst., 2008, 100, 1780-1791.
30. Gunasekera, S. P.; Gunasekera, M.; Longley, R. E.; Schulte, G. K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J. Org. Chem., 1990, 55, 4912-4915. (Pubitemid 20269838)
31. Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents, 2002, 2, 1-17. (Pubitemid 34649866)
32. Kuppens, I.E. Current state of the art of new tubulin inhibitors in the clinic. Curr. Clin. Pharmacol., 2006, 1, 57-70.
33. von Schwarzenberg. K.; Vollmar, A.M. Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett., 2010 Jul 29. Epub ahead of print
34. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products, Nat. Rev. Drug Discov., 2009, 8, 69-85.
35. Williams, P.G.; Buchanan, G.O.; Feling, R.H.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica. J. Org. Chem., 2005, 70, 6196-203. (Pubitemid 41076500)
36. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T.H.; Neuteboom, S.T.; Richardson, P.; Palladino, M.A.; Anderson, K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8 (), 40719.
37. Chauhan, D.; Hideshima, T.; Anderson, K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer, 2006, 95, 961-965. (Pubitemid 44606819)
38. Tsueng, G.; Lam, K.S. A low-sodium-salt formulation for the fermentation of salinosporamides by Salinispora tropica strain NPS21184, Appl. Microbiol. Biotechnol., 2008, 78, 821-826.
39. Pettit, G.R. Progress in the discovery of biosynthetic anticancer drugs. J. Nat. Prod., 1996, 59, 812-821. (Pubitemid 26299178)
40. Wender, P.A.; Cribbs, C.M.; Koehler, K.F.; Sharkey, N.A.; Herald, C.L.; Kamano, Y.; Pettit, G.R.; Blumberg, P.M. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc. Natl. Acad. Sci. (USA), 1988, 85, 7197-7201.
41. Isakov, N.; Galron, D.; Mustelin, T.; Pettit, G.R.; Altman, A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J. Immunol., 1993, 150, 1195-1204. (Pubitemid 23127409)
42. Kortmansky, J.; Schwartz, G.K. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest, 2003, 21, 924-936. (Pubitemid 38055989)
43. Kornblau, S.M.; Konopleva, M.; Andreeff, M. Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert. Opin. Investig. Drugs, 1999, 8, 2027-2057.
44. Wang, S.; Wang, Z.; Boise, L.H.; Dent, P.; Grant, S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia, 1999, 13, 1564-1573. (Pubitemid 29465619)
45. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview= abst-detail-view&confID=23&abstractID=102344.
46. Ajani. J.A.; Jiang, Y.; Faust, J.; Chang, B.B.; Ho, L.; Yao, J.C.; Rousey, S.; Dakhil, S.; Cherny, R.C.; Craig, C.; Bleyer, A., A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest. New Drugs, 2006, 24, 353-357.
47. Winegarden, J.D.; Mauer, A.M.; Gajewski, T.F.; Hoffman, P.C.; Krauss, S.; Rudin, C.M.; Vokes, E.E.A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer, 2003, 39, 191-196. (Pubitemid 36173620)
48. Folkman, J,; Shing, Y. Angiogenesis. J Biol Chem, 1992, 267, 10931-10934.
49. Latreille, J.; Batist, G.; Laberge, F.; Champagne, P.; Croteau, D.; Falardeau, P.; Levinton, C.; Hariton, C.; Evans, W.K.; Dupont, E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin. Lung Cancer, 2003, 4, 231-236. (Pubitemid 36758172)
50. Lu, C.; Lee, J.J.; Komaki, R.; Herbst, R.S.; Feng, L.; Evans, W.K.; Choy, H.; Desjardins, P.; Esparaz, B.T.; Truong, M.T.; Saxman, S.; Kelaghan, J.; Bleyer, A.; Fisch, M.J. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J. Natl. Cancer Inst., 2010, 102, 859-865.
51. Olivera, B.M. w-Conotoxin MVIIA: from marine snail venom to analgesic drug. In Drugs from the Sea (Fusetani, N., ed.), 2000 pp. 75-85, Karger.
52. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products. Nat. Rev. Drug Discov., 2009, 8:69-85.
53. http://www.elan.com/therapies/products/prialt.asp
54. Garber, K. Peptide leads new class of chronic pain drugs. Nature Biotech., 2005, 23, 399. (Pubitemid 41724906)
55. Traynor, K. Eribulin approved for advanced breast cancer. Am. J. Health Syst. Pharm., 2011, 68, 6.
56. Ledford, H. Complex synthesis yields breast-cancer therapy. Nature, 2010, 468, 608-609.
57. Hirata, Y.; Uemura, D. Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl. Chem., 1986, 58, 701-710. (Pubitemid 16557441)
58. Pettit, G.R.; Herald, C.L.; Boyd, M.R.; Leet, J.E., Dufresne, C., Doubek, D.L; Schmidt, J.M.; Cerny, R.L.; Hooper, J.N.A., Rutzler, K.C. Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J. Med. Chem., 1991, 34, 3339-3340.
59. Aicher, T.D.; Buszek, K.R.; Fang, F.G.; Forsyth, C.J.; Jung, S.H.; Kishi, Y.; Matelich, M.C.; Scola, P.M.; Spero, D.M.; Yoon, S.K. Total Synthesis of Halichondrin B and Norhalichondrin B. J. Am. Chem. Soc., 1992, 114, 3162.
60. Seletsky, B.M.; Wang, Y.; Hawkins, L.D.; Palme, M.H.; Habgood, G.J.; DiPietro, L.V.; Towle, M.J.; Salvato, K.A.; Wels, B.F.; Aalfs, K.K.; Kishi, Y.; Littlefield, B.A.; Yu, M.J. Structurally simplified macrolactone analogues of halichondrin B. Bioorg. Med. Chem. Lett., 2004, 14, 5547-5550. (Pubitemid 39346342)
61. Jimeno, A. Eribulin: rediscovering tubulin as an anticancer target. Clin. Cancer Res., 2009, 15, 3903-3905.
62. Dabydeen, D.A.; Burnett, J.C.; Bai, R.; Verdier-Pinard, P.; Hickford, S.J.; Pettit, G.R.; Blunt, J.W.; Munro, M.H.; Gussio, R.; Hamel, E. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol., 2006, 70, 1866-1875. (Pubitemid 44771902)
63. Towle, M.J.; Salvato, K.A.; Wels, B.F.; Aalfs, K.K.; Zheng, W.; Seletsky, B.M.; Zhu, X.; Lewis, B.M.; Kishi, Y.; Yu, M.J.; Littlefield, B.A. Eribulin induces irreversible mitotic blockade: Implications of cell-based pharma-codynamics for In vivo efficacy under intermittent dosing conditions. Cancer Res., 2011, 71, 496-505.
64. Twelves, C.; Cortes, J.; Vahdat, L.T.; Wanders, J.; Akerele, C.; Kaufman, P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer, 2010, 10, 160-163.
65. Vahdat, L.; Pruitt, B.; Fabian, C.J.; Rivera, R.R.; Smith, D.A.; Tan-Chiu, E.; Wright, J.; Tan, A.R.; Dacosta, N.A.; Chuang, E.; Smith, J.; O'Shaughnessy, J.; Shuster, D.E.; Meneses, N.L.; Chandrawansa, K.; Fang, F.; Cole, P.E.; Ashworth, S.; Blum, J.L. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2009, 27, 2954-2961.
66. Cortes, J.; Vahdat, L.; Blum, J.L.; Twelves, C.; Campone, M.; Roché, H.; Bachelot, T.; Awada, A.; Paridaens, R.; Goncalves, A.; Shuster, D.E.; Wanders, J.; Fang, F.; Gurnani, R.; Richmond, E.; Cole, P.E.; Ashworth, S.; Allison, M.A. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol., 2010, 28, 3922-3928.
67. Arnold, S.M.; Moon, J.; Williamson, S.K.; Atkins, J.N.; Ou, S.H.; Leblanc, M.; Urba, S.G.; Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest. New Drugs, 2009, Nov 25 [Epub ahead of print].
68. http://dtp.nci.nih.gov/ (Accessed February 12, 2011).
69. Rinehart, K.L. Antitumor compounds from tunicates. Med. Res. Rev. 2000, 20, 1-27. (Pubitemid 30027559)
70. D'Incalci, M.; Galmarini, C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther., 2010, 9, 2157-2163.
71. Vincenzi, B.; Napolitano, A.; Frezza, A.M.; Schiavon, G.; Santini, D.; Tonini, G. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics, 2010, 11, 865-878.
72. de Boer, J.; van Steeg, H.; Berg, R.J.; Garssen, J.; de Wit, J.; van Oostrum, C.T.; Beems, R.B.; van der Horst, G.T.; van Kreijl, C.F.; de Gruijl, F.R.; Bootsma, D.; Hoeijmakers, J.H.; Weeda, G. Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition. Cancer Res., 1999, 59, 3489-3494. (Pubitemid 29334513)
73. Erba, E.; Bergamaschi, D.; Bassano, L.; Damia, G.; Ronzoni, S.; Faircloth, G.; D'Incalci, M. Ecteinascidin-743 (Yondelis), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer, 2001, 37, 97-105. (Pubitemid 32119366)
74. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000773/human-med-001165.jsp&murl=menus/medicines/medicines. jsp&jsenabled=true Doc.Ref.: EMEA/706735/2009 EMEA/H/C/773 (Accessed February 12, 2011).
75. http://rarediseases.about.com/b/2004/10/10/yondelis-granted-fda-orphan- drug-status.htm. (Accessed February 12, 2011).
76. Soini, E.J.; García San Andrés, B.; Joensuu, T. Trabectedin in the treatment of: cost-effectiveness, cost-utility and value of information. Ann. Oncol., 2011, 22, 215-223.
77. Brüning, A.; Mylonas, I. New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer. Arch. Gynecol. Obstet., 2010, Nov 17. [Epub ahead of print].
78. Demetri, G.D.; Chawla, S.P.; von Mehren, M.; Ritch, P.; Baker, L.H.; Blay, J.Y.; Hande, K.R.; Keohan, M.L.; Samuels, B.L.; Schuetze, S.; Lebedinsky, C.; Elsayed, Y.A.; Izquierdo, M.A.; Gómez, J.; Park, Y.C.; Le Cesne, A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J. Clin. Oncol., 2009, 27, 4188-4196.
79. McMeekin, D.S.; Lisyanskaya, A.; Crispens, M.; Oza, A.M.; Braly, P.; Doering, D.; Bayever, E.; Michiels, B.; Markman, M. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecol. Oncol, 2009, 114, 288-292.
80. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting- Materials/Drugs/OncologicDrugsAdvisoryCommittee/UCM171149.pdf. (Accessed February 12, 2011).
81. Cuadrado, A.; Garcia-Fernandez, L.F.; Gonzalez, L.; Suarez, Y.; Losada, A.: Alcaide, V.; Martinez, T.; Fernandez-Sousa, J.M.; Sanchez-Puelles, J.M.; Munoz, A. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J. Biol. Chem., 2003, 278, 241-250. (Pubitemid 36043568)
82. Garcia-Fernandez, L.F.; Losada, A.: Alcaide, V.; Alvarez, A.M.; Cuadrado, A.; González, L.; Nakayama, K.; Nakayama, K.I.; Fernandez-Sousa, J.M.; Muñoz, A.: Sanchez-Puelles, J.M. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene, 2002, 21, 7533-7544. (Pubitemid 35305581)
83. Cuadrado, A.; Gonzalez, L.; Suarez, Y.; Martinez, T.; Munoz, A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene, 2004, 23, 4673-4680. (Pubitemid 38859456)
84. Geldof, A.A.; Mastbergen, S.C.; Henrar, R.E.; Faircloth, G.T. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother. Pharmacol., 1999, 44, 312-318. (Pubitemid 29402201)
85. Erba, E.; Bassano, L.; Di Liberti, G.; Muradore, I.; Chiorino, G.; Ubezio, P.; Vignati, S.; Codegoni, A.; Desiderio, M.A.; Faircloth, G.; Jimeno, J.; D'Incalci, M. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br. J. Cancer, 2002, 86, 1510-1517. (Pubitemid 34548077)
86. Crews, C.M.; Lane, W.S.; Schreiber, S.L. Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. (USA), 1996, 93, 4316-4319. (Pubitemid 26144283)
87. Broggini, M.; Marchini, S.V.; Galliera, E., Borsotti, P.; Taraboletti, G.; Erba, E.; Sironi, M.; Jimeno, J.; Faircloth, G.; Giavazzi, R.; D'Incalci, M. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukaemia cells MOLT-4. Leukemia, 2003, 17, 52-59. (Pubitemid 36175888)
88. Erba, E.; Serafini, M.; Gaipa, G.; Tognon, G.; Marchini, S.; Celli, N.; Rotilio, D.; Broggini, M.; Jimeno, J.; Faircloth, G.; Biondi, A.; D'Incalci, M. Effect of Aplidin in acute lymphoblastic leukaemia cells. Br. J. Cancer, 2003, 89, 763-773. (Pubitemid 37076186)
89. Taddei, M.L.; Chiarugi, P.; Cuevas, C.; Ramponi, G.; Raugei, G. Oxidation and inactivation of low molecular weight protein tyrosine phosphatase by the anticancer drug Aplidin. Int. J. Cancer, 2006, 118, 2082-2088.
90. Gonzalez-Santiago, L.; Suarez, Y.; Zarich, N.; Munoz-Alonso, M.J; Cuadrado, A.; Martinez, T.; Goya, L.; Iradi, A.; Saez-Tormo, G.; Maier, J.V.; Moorthy, A.; Cato, A.C.; Rojas, J.M.; Muñoz; A. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ., 2006, 13, 1968-1981. (Pubitemid 44542409)
91. Jimeno, J.; Lopez-Martin, J.A.; Ruiz-Casado, A.; Izquierdo, M.A.; Scheuer, P.J.; Rinehart, K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs, 2004, 15, 321-329. (Pubitemid 38526755)
92. Le Tourneau, C.; Raymond, E.; Faivre, S. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr. Pharm. Des., 2007, 13, 3427-3439. (Pubitemid 350201676)
93. Wieser, T.; Deschauer, M.; Olek, K.; Hermann, T.; Zierz, S. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology, 2003, 60, 1351-1353. (Pubitemid 36460994)
94. Le Tourneau, C.; Faivre, S.; Ciruelos, E.; Domínguez, M.J.; López-Martín, J.A.; Izquierdo, M.A.; Jimeno, J.; Raymond, E. Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. Am. J. Clin. Oncol., 2010, 33, 132-136.
95. Mateos, M.V.; Cibeira, M.T.; Richardson, P.G.; Prosper, F.; Oriol, A.; de la Rubia, J.; Lahuerta, J.J.; García-Sanz, R.; Extremera, S.; Szyldergemajn, S.; Corrado, C.; Singer, H.; Mitsiades C.; Anderson, K.C.; Bladé J.; San Miguel, J. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin. Cancer Res., 2010, 16, 3260-3269.
96. Dumez, H.; Gallardo, E.; Culine, S.; Galceran, J.C.; Schöffski, P.; Droz, J.P.; Extremera, S.; Szyldergemajn, S.; Fléchon, A. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar. Drugs; 2009, 16, 451-463.
97. Baudin, E.; Droz, J.P.; Paz-Ares, L.; van Oosterom, A.T.; Cullell-Young, M.; Schlumberger, M. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am. J. Clin. Oncol., 2010, 33, 83-88.
98. Eisen T, Thomas J, Miller WH Jr, Gore M, Wolter P, Kavan P, Martín JA, Lardelli P. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res., 2009, 19, 185-192.
99. Schöffski, P.; Guillem, V.; Garcia, M.; Rivera, F.; Tabernero, J.; Cullell, M.; Lopez-Martin, J.A.; Pollard, P.; Dumez, H.; del Muro, X.G.; Paz-Ares, L. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar. Drugs, 2009, 7, 57-70.
100. Eisen, T.; Thatcher, N.; Leyvraz, S.; Miller, W.H. Jr.; Couture, F.; Lorigan, P.; Lüthi, F.; Small, D.; Tanovic, A.; O'Brien, M. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer, 2009, 64, 60-65.
101. Peschel, C.; Hartmann, J.T.; Schmittel, A.; Bokemeyer, C.; Schneller, F.; Keilholz, U.; Buchheidt, D.; Millan S.; Izquierdo, M.A.; Hofheinz; R.D. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer, 2008, 60, 374-380.
102. Bai, R.; Friedman, S.J.; Pettit, G.R.; Hamel, E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem. Pharmacol., 1992, 23, 43, 2637-2645.
103. de Arruda, M.; Cocchiaro, C.A.; Nelson, C.M.; Grinnell, C.M.; Janssen, B.; Haupt, A.; Barlozzari, T. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res., 1995, 55, 3085-3092.
104. Newman, R.; Fuentes, A.; Covey, J.; Benvenuto, J. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128). Drug Metab. Dispos., 1994, 22, 428-432. (Pubitemid 24158542)
105. Ray, A.; Okouneva, T.; Manna, T.; Miller, H.P.; Schmid, S.; Arthaud, L.; Luduena, R.; Jordan, M.A.; Wilson, L. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res., 2007, 67, 3767-3776. (Pubitemid 46762163)
106. Garg, V.; Zhang, W.; Gidwani, P.; Kim, M.; Kolb, E.A. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin. Cancer Res., 2007, 13, 5446-5454. (Pubitemid 47510372)
107. Mita, A.C.; Hammond, L.A.; Bonate, P.L.; Weiss, G.; McCreery, H.; Syed, S.; Garrison, M.; Chu, Q.S.;, DeBono, J.S.; Jones, C.B.; Weitman, S.; Rowinsky, E.K. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin. Cancer Res., 2006, 12, 5207-5215. (Pubitemid 44453350)
108. Cunningham, C.; Appleman, L.J.; Kirvan-Visovatti, M.; Ryan, D.P.; Regan, E.; Vukelja, S.; Bonate, P.L.; Ruvuna, F.; Fram, R.J.; Jekunen, A.; Weitman, S.; Hammond, L.A.; Eder, J.P. Jr. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res., 2005, 11, 7825-7833. (Pubitemid 41611627)
109. Ebbinghaus, S.; Rubin, E.; Hersh, E.; Cranmer, L.D.; Bonate, P.L.; Fram, R.J.; Jekunen, A.; Weitman, S.; Hammond, L.A. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res., 2005, 11, 7807-7816. (Pubitemid 41611625)
110. http://www.genzymeoncology.com/onc/research/onc-p-tasidotinHydrochl- oride.asp. (Accessed February 12, 2011).
111. Faircloth, G.; Cuevas, C. Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog. Mol. Subcell. Biol., 2006, 43, 363-379.
112. Cuadros, R.; Montejo de Garcini, E.; Wandosell, F.; Faircloth, G.; Fernandez-Sousa, J.M.; Avila, J. The marine compound Spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett., 2000, 152, 23-29. (Pubitemid 30169014)
113. Baird, R.D.; Clarke, P.A.; Workman, P. ES-285, a novel marine anticancer agent: investigation of mechanism of action using gene expression microarrays. Proc. Am. Assoc. Cancer Res., 2005, 46, Abstract #4111.
114. Sánchez, A.M.; Malagarie-Cazenave, S.; Olea, N.; Vara, D.; Cuevas, C.; Díaz-Laviada, I. Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur. J. Pharmacol., 2008, 584, 237-245.
115. Baird, R.D.; Kitzen, J.; Clarke, P.A.; Planting, A.; Reade, S.; Reid, A.; Welsh, L.; López Lázaro, L.; de las Heras, B.; Judson, I.R.; Kaye, S.B.; Eskens, F.; Workman, P.; deBono, J.S.; Verweij, J. Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol. Cancer Ther., 2009, 8, 1430-1437.
116. Vilar, E.; Grünwald, V.; Schöffski, P.; Singer, H.; Salazar, R.; Iglesias, J.L.; Casado; E.; Cullell-Young, M.; Baselga, J.; Tabernero, J. A phase I doseescalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Invest. New Drugs, 2010, Sep 7 [Epub ahead of print].
117. http://www.cyberlipid.org/extract/extr0008.htm.
118. Macrides, T.A.; Kalafatis, N. Super-critical lipid extract from mussels having anti inflammatory activity. U.S, Patent 6,083,536, July 4, 2000.
119. McPhee, S.; Hodges, L.D.; Wright, P.F.; Wynne, P.M.; Kalafatis, N.; Harney, D.W.; Macrides, T.A. Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculus. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 2007, 146, 346-356.
120. Whitehouse, M.W.; Macrides, T.A.; Kalafatis, N.; Betts, W.H.; Haynes, D.R.; Broadbent J. Anti-inflammatory activity ofa lipid fraction (Lyprinol) from the NZ green-lipped mussel. Inflammopharmacology, 1997, 5, 237-246. (Pubitemid 27459731)
121. Zhang, C.; Betts, W.; Chai, F.; Betts, W.H.; Zalewski, P.D. Lyprinol, a lipid extract from the New Zealand green-lipped mussel, is a lipoxygenase inhibitor that induces apoptosis in human tumour cells. J. Nutr., 2001, 131 (Suppl), 196s (Abstr 1).
122. BBC News | Health | Mussel offers cancer hope - [Sunday, August 1, 1999 Published at 11:07 GMT 12:07 UK, http://news.bbc.co.uk/2/hi/health/409147.stm]. (Accessed February 12, 2011).
123. http://www.cancer.org/docroot/ETO/content/ETO-5-3X-Lyprinol.asp. (Accessed February 12, 2011).
124. Dickson, J.; Pittman, K.; Patterson, K.; Price, T.; Norman, J.; Moldovan, S.; Moretti, K.; Miller, J.; Burfield, G.; Betts, H. A phase 1/2 study of Lyprinol in advanced hormone refractory prostate cancer, and hormone and chemotherapy refractory breast cancer. Proc. Am. Soc. Clin. Oncol., 2002, Abstract 2154.
125. Sukumaran, S.; Pittman, K.B.; Patterson, W.K.; Dickson, J.; Yeend, S., Townsend, A.; Broadbridge, V.; Price, T.J. A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus) lipid extract, in patients with advanced prostate and breast cancer. Ann. Oncol., 2010, 21, 1089-1093.
126. Jensen, P.R.; Mincer, T.J.; Williams, P.G.; Fenical, W. Marine actinomycete diversity and natural product discovery. Antonie Van Leeuwenhoek, 2005, 87, 43-48. (Pubitemid 40331511)
127. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products. Nat. Rev. Drug Discov., 2009, 8, 69-85.
128. Bugni, T.S.; Harper, M.K.; McCulloch, M.W.; Reppart, J.; Ireland, C.M. Fractionated marine invertebrate extract libraries for drug discovery. Molecules, 2008, 19, 13, 1372-1383.
129. Singh, S.B.; Barrett, J.F. Empirical antibacterial drug discovery - Foundation in natural products. Biochem. Pharmacol., 2006, 71, 1006-1015.
130. Larsson, J.; Gottfries, J.; Muresan, S.; Backlund, A. ChemGPS-NP: Tuned for navigation in biologically relevant chemical space. J. Nat. Prod., 2007, 70, 789-794. (Pubitemid 46953601)
131. Henkel, T.; Brunne, R.M.; Muller, H.; Reichel, F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew. Chem. Int. Ed., 1999, 38, 643-647. (Pubitemid 29129819)
132. Verdine, G. The combinatorial chemistry of nature. Nature, 1996, 384, 11-13. (Pubitemid 26374532)
133. Tulp, M.; Bohlin, L. Unconventional natural sources for future drug discovery. Drug Discov. Today, 2004, 9, 450-458. (Pubitemid 38510564)
134. Feher, M.; Schmidt, J.M. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci., 2003, 43, 218-227.
135. Corey, E.J.; Gin, D.Y.; Kania, R.S. Enantioselective Total Synthesis of Ecteinascidin 743. J. Am. Chem. Soc., 1996, 118, 9202-9203. (Pubitemid 26342569)
136. http://www.google.it/imgres?imgurl=http://media.diagnosispro.com/drugs/ 20100408-9dc35c59-f4f3-43b4-8251-0cf5c06cdc80/gemzar-f001-v1.jpg&imgrefurl=
137. http://www.pfeist.net/ALL/arac/sea2arac2.html.
138. http://en.diagnosispro.com/drug-information-for/gemzar-gemcitabine-hcl- for-injection-eli-lilly-and-company-description/3390-241412.
139. http://www.google.it/imgres?imgurl=http://www.jbl.de/images/gallery/ container/std/39-1657.jpg&imgrefurl.
140. http://www.google.it/imgres?imgurl=http://4.bp.blogspot.com/ -PiEbciaM-tBE/TBNhH5izl4I/AAAAAAAAAyI/wheROe6yMH4/s320/Eribulin%2Bmesylate%2B- 01.GIF&imgrefurl.
141. http://www.google.it/imgres?imgurl=http://www.chemdrug.com/databases/ SYNTHESIS/SYN/28/28719801i.gif&imgrefurl.
142. http://www.google.it/imgres?imgurl=http://www.chem-station.com/ chemist-db/images/halicondrinB.gif&imgrefurl.
143. http://www.google.it/imgres?imgurl=http://i293.photobucket.com/albums/ m53/nexavar/trabectedin/743px-Trabectedin-.png&imgrefurl.
144. http://www.torinoscienza.it/dossier/nuovi-farmaci-dagli-abissi-4703.
145. http://www.google.it/imgres?imgurl=http://www.mesa.edu.au/seaweek2011/ images/Aplidium-albicans.jpg&imgrefurl
146. http://www.google.it/imgres?imgurl=http://www.translational-medicine.com / content/figures/1479-5876-4-3-3.gif&imgrefurl=
147. http://www.chemdrug.com/databases/8-0-doditgutmjvfmnyn.html.
148. http://www.scbt.kr/datasheet-201449-dolastatin-15.html.
149. http://www.mayotte-photos-plongee.com/article-lievre-de-mer-dolabella- auricularia-de-l-ocean-indien-a-mayotte-52390813.html.
150. http://www.google.it/imgres?imgurl=http://www.aquarium.co.jp/shell/ galle-ry/nagaubagai.jpg&imgrefurl=http://www.aquarium.co.jp/shell/gallery/ hyouzi.php%3Fnakama%3Dbakagai&usg=-.
151. http://www.chemdrug.com/databases/9-0-uqrosqqqigvmckii.html.
152. http://www.sea-ex.com/fishphotos/mussels,1.html.